As Biotechnology businesses, Audentes Therapeutics Inc. (NASDAQ:BOLD) and Albireo Pharma Inc. (NASDAQ:ALBO), are affected by contrast. This especially applies to their institutional ownership, earnings and valuation, profitability, risk, dividends, analyst recommendations.
Earnings and Valuation
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Audentes Therapeutics Inc.||36||0.00||N/A||-3.79||0.00|
|Albireo Pharma Inc.||30||109.43||N/A||-5.11||0.00|
Table 1 shows the gross revenue, earnings per share (EPS) and valuation for Audentes Therapeutics Inc. and Albireo Pharma Inc.
Table 2 shows us the return on equity, return on assets and net margins of both companies.
|Net Margins||Return on Equity||Return on Assets|
|Audentes Therapeutics Inc.||0.00%||-40.8%||-37.4%|
|Albireo Pharma Inc.||0.00%||-47%||-32.3%|
The Current Ratio and Quick Ratio of Audentes Therapeutics Inc. are 14.3 and 14.3 respectively. Its competitor Albireo Pharma Inc.’s Current Ratio is 15.5 and its Quick Ratio is 15.5. Albireo Pharma Inc. can pay off short and long-term obligations better than Audentes Therapeutics Inc.
The following table given below contains the ratings and recommendations for Audentes Therapeutics Inc. and Albireo Pharma Inc.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|Audentes Therapeutics Inc.||0||0||1||3.00|
|Albireo Pharma Inc.||0||0||1||3.00|
$48 is Audentes Therapeutics Inc.’s consensus target price while its potential upside is 40.85%. Competitively the consensus target price of Albireo Pharma Inc. is $62, which is potential 173.49% upside. Based on the analysts opinion we can conclude, Albireo Pharma Inc. is looking more favorable than Audentes Therapeutics Inc.
Insider and Institutional Ownership
Audentes Therapeutics Inc. and Albireo Pharma Inc. has shares owned by institutional investors as follows: 0% and 79.2%. About 1.3% of Audentes Therapeutics Inc.’s share are owned by insiders. Competitively, Albireo Pharma Inc. has 0.2% of it’s share owned by insiders.
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Audentes Therapeutics Inc.||-1.57%||1.22%||4.6%||62.23%||5.7%||82.55%|
|Albireo Pharma Inc.||-8.55%||-18.74%||-26.39%||6.63%||-17.55%||5.54%|
For the past year Audentes Therapeutics Inc. was more bullish than Albireo Pharma Inc.
Audentes Therapeutics, Inc., a biotechnology company, focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects in the United States. The company is developing AT132 for the treatment of X-linked myotubular myopathy; AT342 for the treatment of crigler-najjar syndrome type 1; AT982 for the treatment of pompe disease; and AT307 for the treatment of the CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia. Audentes Therapeutics, Inc. has a collaboration with the University of Pennsylvania for the treatment of Crigler-Najjar. The company was founded in 2012 and is headquartered in San Francisco, California.
Albireo Pharma, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI) disorders in the United States. Its lead product candidate includes A4250, an orally administered ileal sodium dependent bile acid transporter (IBAT) inhibitor that is in phase II clinical trial for treating progressive familial intrahepatic cholestasis and primary biliary cholangitis. The companyÂ’s clinical-stage product candidates comprise Elobixibat, an orally administered IBAT inhibitor, which is in Phase III clinical trial for the treatment of chronic constipation and other GI diseases; and A3384, a development stage product to treat bile acid malabsorption. It has license agreement with EA Pharma for the development and commercialization of elobixibat. Albireo Pharma, Inc. is headquartered in Boston, Massachusetts.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.